Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 4, 2025
Data Byte

Bispecifics overtake ADCs in China deals

Western biopharmas signed more deals for bispecifics than ADCs with China biotechs last year
BioCentury | Jan 24, 2025
Finance

Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs

In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Jan 6, 2025
Regulation

2024 Approvals: Where are the new modalities?

Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Oct 31, 2024
Data Byte

Seven PDUFA dates on FDA’s November calendar

Upcoming decisions include BridgeBio’s 
BioCentury | Sep 18, 2024
Product Development

Data from Merck, Daiichi could support first approval for HER3 ADC

In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more
BioCentury | Aug 30, 2024
Finance

Finance Report: RA, Forbion back immunology play Navigator to develop bispecific 

Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO
BioCentury | Aug 20, 2024
Product Development

Clinical Report: Lilly’s tirzepatide shows benefit in pre-diabetics

Plus: Updates on BioNTech, MediLink, Pfizer and Incyte
BioCentury | Jun 19, 2024
Product Development

Clinical Report: Zentalis hold resurfaces WEE1 safety concerns

Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | Jun 5, 2024
Data Byte

15 PDUFA dates on FDA’s roster in June

Upcoming decisions include HER3 ADC from Daiichi-Merck and full approval for Sarepta’s DMD gene therapy 
BioCentury | May 24, 2024
Product Development

Clinical Report: Merus data stand out among ASCO highlights

Clinical data released ahead of ASCO from Merus, Caribou, BioNTech and more
Items per page:
1 - 10 of 71